Real-World Effectiveness and Safety of Anifrolumab in Egyptian Patients with Moderate-to-Severe Systemic Lupus Erythematosus: A Retrospective Multicenter Study
Authors:
- Samar TharwatSTSamar Tharwat
- Samah A. El BakrySBSamah A. El Bakry
- Shereen Abdelsalam OlwanSOShereen Abdelsalam Olwan
- Fatma FayedFFFatma Fayed
- Enas S. ZahranEZEnas S. Zahran
- Maie HelalMHMaie Helal
- Mai M. MorsyMMMai M. Morsy
- Abeer Abdelmonem ShahbaASAbeer Abdelmonem Shahba
- Rehab ElnemrRERehab Elnemr
- Nehad Mohamed ElshatbyNENehad Mohamed Elshatby
- Nevine MohannadNMNevine Mohannad
- Gehad MaghrabyGMGehad Maghraby
Open Access
- 17 September 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7241
Abstract
Background and Objectives: Real-world data on anifrolumab in Egyptian patients with moderate-to-severe systemic lupus erythematosus (SLE) remain limited. This study aimed to evaluate the real-world effectiveness and safety of anifrolumab in Egyptian patients with moderate-to-severe SLE. Materials and Methods: This retrospective, multicenter, observational cohort study reviewed the medical records of 80 adults with moderate-to-severe SLE who had received at least 6 doses (≥20 weeks) of intravenous anifrolumab 300 mg every 4 weeks as part of routine clinical care at 13 Egyptian tertiary rheumatology centers; medical record review and data extraction were performed between May and July 2026. Outcomes were assessed at baseline and final follow-up and included disease activity, lupus low disease activity state (LLDAS), glucocorticoid use, flare status, laboratory parameters, and adverse events. Results: Patients were predominantly female (98.8%), with a mean age of 30.4 ± 9.8 years. Disease activity improved, with SLEDAI-2K decreasing from 11 to 4 (p < 0.001), PGA from 2.7 to 0.5 (p < 0.001), LLDAS increasing from 0% to 51.3% (p < 0.001), and flares decreasing from 95.0% to 18.8% (p < 0.001). Glucocorticoid burden also declined, with oral glucocorticoid use falling from 95.0% to 83.8% (p = 0.021), median prednisone dose from 20 mg/day to 5 mg/day (p < 0.001), intravenous methylprednisolone use from 50.0% to 6.3% (p < 0.001), and 63.8% achieving prednisone doses ≤ 7.5 mg/day (p < 0.001). Laboratory improvement included hemoglobin, leukocyte count, lymphocyte count, platelet count, C3, C4, anti-dsDNA, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), while serum creatinine did not change significantly (p = 0.904). No serious adverse events were reported. Conclusions: Anifrolumab was associated with significant short-term improvement in clinical and laboratory disease activity, marked steroid sparing, and reduced flare burden in Egyptian patients with moderate-to-severe SLE, with acceptable short-term tolerability.Keywords
This publication has 32 references indexed in Scilit:
- From pathogenesis to precision medicine in systemic lupus erythematosus: Emerging biomarkers and targeted interventionsiScience, 2026
- Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 StudyArthritis & Rheumatology, 2026
- Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reductionImmunological Medicine, 2025
- A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusArthritis & Rheumatology, 2022
- Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trialsThe Lancet Rheumatology, 2022
- Type I interferon in the pathogenesis of systemic lupus erythematosusCurrent Opinion in Immunology, 2020
- Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric propertiesRheumatology, 2020
- Trial of Anifrolumab in Active Systemic Lupus ErythematosusNew England Journal of Medicine, 2020
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialThe Lancet Rheumatology, 2019
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981